Posts Tagged ‘alternatives to surgery Basal Cell Carcinoma’
I have recently been diagnosed with skin cancer. I have a basal cell carcinoma about the size of a pencil eraser on the side of my nose which I will be treating with Curaderm. I was introduced to Curaderm by a friend who has successfully used this to treat a number of squamous cell skin cancers on his face and neck. After the treatment it left no visible scarring unlike the two previous surgical procedures he had in which he ended up needing skin grafts which left much visible scarring.
I have been doing much research on skin cancer and alternative treatments since being diagnosed myself and although it is a scary news to get from your doctor I will tell you that most forms of non melanoma skin cancers can be treated with a great deal of success using conventional methods. The only problem with conventional methods is that most if not all procedures are invasive and require surgery. If my skin cancer had been anywhere but on my face I most likely would have opted for a surgical procedure for removal but because of the location of the cancer it forced me to do research on alternative treatments which is when my friend introduced me to Curaderm.
I can live with a little scarring but I dont know how I would deal with losing my nose and it has happened in some skin cancer cases. I know, I should think positive but its in my nature to always assume the worst and anything above that then becomes a bonus.
Just began my treatment yesterday on a chest lesion. It does seem to be pulling a gray milky fluid out and the area is getting very red and slightly swollen. Connecting with others is helpful.
I have used this cream. I started using it the second week in April 2011. It has worked beautifully!! I”m very pleased and amazed!! It did take until the middle of August( almost five months), but I think that was my fault for initially ending the treatment too soon. I wanted to avoid surgery, as the lesion was on my nose and I was worried about scarring.
I have no scarring at all, the lesion has entirely disppeared. I would highly recommend it to anyone.
Dr. Wright: Studies have shown that an extract from eggplant called BEC5 can cure — that’s cure, not just improve — cases of actinic keratosis (and the majority of skin cancers too)
Q: I was very interested to read your article about BEC5 and skin cancer in the December 2005 issue of Nutrition & Healing. I have been following developments concerning this natural material closely since older relatives have eliminated their own skin cancers with an earlier version of BEC5.
Q: I have several dry, rough patches on the back of one of my hands that look almost like they have brownish scales on them. It’s not itchy and it doesn’t seem like psoriasis, but I was wondering if you had any information on what it could be?
Dr. Wright: You should definitely have a dermatologist check them out to be sure, but the spots you’re describing sound like a condition called actinic keratosis.
Studies have shown that an extract from eggplant called BEC5 can cure — that’s cure, not just improve — cases of actinic keratosis (and the majority of skin cancers too), usually in two to three months.
To read more about BEC5, refer back to the December 2005 issue of Nutrition & Healing
United Kingdom Hospitals Dermatologist Clinical Trial
Dermatology Department 2nd Floor Outpatient Building
Hospital White Chapel London, E1 1BB
Tuesday April 23rd 2002
CLINICAL APPRAISAL of BEC5
You have requested us to detail our clinical experience with BEC5 in the treatment of malignant lesions of the skin. We understand that this may be shown to potential purchasers of BEC5.
The Dermatology Department at the Royal London Hospital has acted as an approved and designated center in two clinical trials to determine the safety and efficacy of BEC 5 cream in the treatment of cancerous lesions of the skin. In the first of these, a pivotal double blind randomized study; Royal London recruited, treated and monitored 21 of the 94 patients. In the second trial, comprising 41 patients, Royal London was the sole designated centre. This trial was an open study, conducted primarily assess the safety of the product. Herewith we summarize our observation on the use, safety, efficacy, cosmetic result and resource effectiveness of the product.
The trials were formally restricted to patients diagnosed by physician as having superficial basal cell carcinoma. Hence patients with morpheoic lesions were excluded. However subsequently conducted punch biopsy results demonstrated that several trial patients did in deed have basal cell carcinoma. Even so our findings in respect of these patients were that successful treatment of the invasive form of basal cell carcinoma paralleled the general success rate of BEC5 ie, around 78%.
In our view these results, in the least justify a more extensive clinical trial of BEC5 against such cancers. We note in this respect that treatment of the morpheoic form of the affliction is presently confined to surgical removal. We are not aware of any emerging therapy, for example, photodynamic therapy that has the potential to extend to treatment of other than superficial skin cancers.
Our clinical experience has shown that BEC5 is safe. In the two frequent (twice daily) and prolonged (8 weeks) application of a cream incorporating BEC5 under occlusive dressing resulted only in local skin irritation and erythema. Very few patients under our supervision withdrew from treatment on this account. Hence we consider treatment with BEC5 to be safe therapy.
Furthermore, patient blood and urine was analyzed using very sensitive methods to determine the presence of the BEC5 during and after a standard treatment regime (twice daily for 8 weeks). Such analysis produced no evidence of the active pharmaceutical ingredients to BEC5 or their breakdown products. Hence, it was concluded that there is no systemic absorption of BEC5. This is extremely important from the clinical perspective and may be contrasted with other topical preparations. For example, 5 fluouracil shows systemic absorption and can prove to be toxic when used with large lesions.
Royal London has a large dedicated skin cancer clinic as it is a Skin Cancer Center for the North East Thames Network. This fact, coupled with the results of the first trial, was instrumental on Royal London”s conduct of second open study. Success rates in this open trial paralleled the multi-center efficacy rate of 78%. Success was defined as zero presence of basal cell carcinoma after histological examination of samples extracted from the lesion site by punch biopsy.
We consider that this rate of treatment success more than justifies the physician considering BEC5 as an alternative to currently predominant treatment such as surgical excision or cryotherapy.
BEC results in ulceration of the lesion site during treatment. However, we have observed that post treatment the wound is quickly replenished with normal tissue and that residual scarring is minimal. Whether such scarring proves more or less extensive than that consequent upon surgical excision is dependant on a number of factors including lesion size, location and so on. However, it can be said that the cosmetic results offered by treatment with BEC5 are comparable to that resulting from surgical excision.
Basal Cell Carcinoma is a slow growing locally invasive malignant skin tumor which mainly affects Caucasians. Dermatologists, plastic surgeons and radiotherapists jointly manage the affliction, such management usually involves surgery. The risks of surgical intervention are well known.
Moreover, excision of basal cell carcinoma from the facial area often involves reconstructive, which can be both time consuming and costly. Hence an alternative, safe and efficacious method of treatment of basal cell carcinoma that does not require physician or hospital attendance must be encouraged.
In our view and experience BEC5 is a topical preparation, which is safe and effective, ideal therapy for outpatient treatment. Hence BEC5 is a much needed alternative to surgery for basal cell carcinoma. This is the commonest cancer in Caucasians worldwide and the prevalence continues to increase with an increasing ageing population. It is a cost effective treatment for both primary and secondary skin cancer care.
We trust that the following is adequate for your purposes
Rino Cerio BS (Lond) FRCP (Edin) FRCPath Consultant Dermatologist and Senior Lecturer in Dermatopathology
Dr. Sangeeta Punjabi MBBS, DVD, DipNB (Dermatology) Research Registrar, Royal London Hospital
NOTE: This is a transcript of the clinical evaluation of by
Barts And The London NHS – NHS Trust
Curaderm BEC5 is also a cream used to treat superficial Basal Cell Carcinomas, and is made up of 99.8% natural ingredients. The active ingredient in Curaderm BEC5 is 0.005% Solasodine Glycoside which is extracted from Aubergines (Egg plants) and a plant called Devil”s Apple (in Latin, Solanum linnaeanum).
I first noticed a small red mark (less than 1 cm) on my forehead about 7 years ago. I wasn”t concerned about it and so didn”t seek any medical advice. About 5 years ago the mark was still there and slightly bigger so I decided to see a dermatologist who prescribed Efudix cream. The cream didn”t seem to have any effect so I stopped using it.
After doing nothing about the Basal Cell Carcinoma for a further couple of years I decided to see another dermatologist who said that surgery was the only way to get rid of the Basal Cell Carcinomaas it was so large. I did all the regular examinations before the surgery (blood test, x-rays etc..) but then just before the scheduled surgery I got another job which meant I was away from home 6 days a week, so I didn”t do the surgery.
After another year (I managed to get a better job closer to home) I went back to the same dermotologist who (after severely repremanding me) sent me to a specialist cancer clinic.
It was at about this time, after researching alternatives to surgery for my Basal Cell Carcinoma, I came across Curaderm BEC5.